Feline Dementia: Synaptic Evidence Linking Cats to Alzheimer's Disease

In older cats, amyloid-β deposits accumulate within the synapses themselves, immediately followed by their phagocytosis by microglia and, to a lesser extent, by astrocytes.By examining 25 cat brains postmortem, a study identifies the cat as a promising natural model for studying and treating the disease in humans. Synaptic loss predicts declines in memory and executive function in Alzheimer’s disease. Microglia, the brain’s immune cells, carry out synaptic pruning that is beneficial for development but can become harmful in pathological contexts, particularly in the presence of β-amyloid. Several studies identify this microglial pruning as central to synaptic dysfunction in various neurological disorders.  

A pathology “at the synapse level,” documented in postmortem tissue

Using immunolabeling and high-resolution imaging, the study visualizes amyloid-β in synapses and demonstrates its colocalization with markers of glial phagocytosis: microglia capture presynaptic and postsynaptic elements, a hallmark of pathological “pruning.” This tandem signal (synaptic Aβ deposition and glial phagocytosis) corresponds to the sequence described in humans and suggests a direct mechanism of connectivity loss.  

A cascade of molecular events already described

This convergence is not isolated: in mouse models of Alzheimer’s disease, perivascular cells overexpress the glycoprotein SPP1/osteopontin at the precise moment when microglia shift to a highly phagocytic state, activating complement pathways and thereby accelerating synaptic engulfment. Inhibiting SPP1 attenuates these states and preserves synaptic contacts. The feline observation provides comparative in situ validation of a pattern already established in mice: Aβ → SPP1 → phagocytic microglia → synaptic loss.  

Why the cat is a game-changer: a model that ages “naturally”

Unlike transgenic rodents, cats age naturally and spontaneously develop a clinical syndrome of dementia. Here, the key lesions (intrasynaptic Aβ) and the effector response (phagocytosis by microglia/astrocytes) are detected in brain tissue and at the synapses—that is, at the anatomical site most closely correlated with cognitive decline. In this sense, feline dementia provides a more accurate translational model for evaluating interventions aimed at synaptic protection, microglial modulation, or Aβ clearance.  

Concrete therapeutic targets: modulating glia, saving the synapse

Several strategies are possible: controlling SPP1/TREM2-complement-induced microglial states, inhibiting the complement cascade in the synaptic vicinity, and accelerating Aβ degradation. Research teams are already testing human microglia derived from iPSCs (induced pluripotent stem cells) to secrete neprilysin, an enzyme that degrades amyloid, resulting in a reduction in amyloid burden and protection of synapses in preclinical models. The cat, due to its spontaneous pathology and aging kinetics, is a logical test bed prior to human clinical translation.  

Preliminary findings to be confirmed

The study remains postmortem and has a modest sample size; it establishes strong associations between synaptic Aβ and glial phagocytosis without capturing the causal dynamics. The next steps include in vivo synaptic monitoring, the use of biomarkers sensitive to the Aβ-glial axis, and intervention strategies targeting microglia and the complement system. The value of this human/feline comparative design lies in testing mechanisms at the same anatomical level—the synapse—where molecules often fail due to poorly selected targets.   By documenting this lesion-effect colocalization at the synaptic level, feline dementia emerges as a strategic natural model for therapies targeting glia and the synapse—where memory is formed.